Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Intravenous...

    Intravenous eptinezumab may prevent migraine for 3 months confirms phase 3 trial

    Written by Medha Baranwal Baranwal Published On 2019-08-14T20:27:38+05:30  |  Updated On 14 Aug 2019 8:27 PM IST
    Intravenous eptinezumab may prevent migraine for 3 months confirms phase 3 trial

    USA: Intravenous eptinezumab, an anti‐CGRP (calcitonin gene-related peptide) monoclonal antibody, showed efficacy for the prevention of chronic migraine headache for 3 months in a dose-ranging, phase 3 trial.


    The study was published in the journal Headache and presented at the annual meeting of the American Headache Society.


    Migraine is a chronic neurologic disorder that affects about 12 to 14% of people worldwide, It involves periodic attacks of head pain along with symptoms that may include nausea as well as sensitivity to light and sound. More than three-quarters of migraine sufferers experience at least one migraine attack per month, and more than half are severely impaired during their attacks.


    Laszlo L. Mechtler, DENT Neurologic Institute, Amherst, NY, USA, and colleagues reported the change from baseline in mean monthly migraine days (MMDs) and mean monthly headache days (MHDs) over the first 2 infusions in patients treated in PROMISE‐1 or PROMISE‐2 trials.


    For the study, patients with episodic migraine (PROMISE‐1) or chronic migraine (PROMISE‐2) were randomized to receive repeated doses of eptinezumab 100mg, 300mg, or placebo (or 30mg in EM trial). The doses were administered intravenously every 12 weeks for up to 4 (PROMISE‐1) or 2 (PROMISE‐2) infusions.


    The primary endpoint in both studies was the change from baseline in MMDs (captured via daily eDiary) over Weeks 1‐12 (Months 1‐3), with headache days captured as a secondary endpoint in the daily eDiary.


    A migraine day was defined as any day with a headache that met the International Classification of Headache Disorders criteria for migraine; a headache day was defined as any day with a headache, including those with migraine.


    In PROMISE‐1 (100mg, n=221; 300mg, n=222; placebo, n=222), mean MMDs and MHDs at baseline were ~8.6 and ~10.0, respectively, across treatment groups.


    Findings for PROMISE-1 trial

    • Over the first infusion (Months 1‐3), the mean changes from baseline in MMDs were ‐3.9 (100mg), ‐4.3 (300mg), and ‐3.1 (placebo) and in MHDs were ‐4.0 (100mg), ‐4.5 (300mg), and ‐3.3 (placebo).

    • Over the second infusion (Months 4‐6), the mean changes from baseline in MMDs were ‐4.6 (100mg), ‐4.8 (300mg), and ‐3.6 (placebo) and in MHDs were ‐5.2 (100mg), ‐5.3 (300mg), and ‐4.2 (placebo).


    In PROMISE‐2 (100mg, n=356; 300mg, n=350; placebo, n=366), mean MMDs and MHDs at baseline were ~16.1 and ~20.4, respectively, across treatment groups.


    Findings for PROMISE-2 trial




    • Over the first infusion (Months 1‐3), the mean changes from baseline in MMDs were ‐7.8 (100mg), ‐8.3 (300mg), and ‐5.8 (placebo) and in MHDs were ‐8.2 (100mg), ‐8.8 (300mg), and ‐6.4 (placebo).

    • Over the second infusion (Months 4‐6), the mean changes from baseline in MMDs were ‐8.3 (100mg), ‐9.0 (300mg), and ‐6.3 (placebo) and in MHDs were ‐9.5 (100mg), ‐10.5 (300mg), and ‐8.0 (placebo).


    "In both PROMISE‐1 and PROMISE‐2, the mean change from baseline in MMDs and MHDs increased through the second infusion, demonstrating an increase in the efficacy with subsequent infusion. With the second infusion, the changes in MHDs paralleled the changes in MMDs," concluded the authors.


    Source: Headache. 2019 June;59[S1]:34, Abstract P12 by Mechtler LL et al.
    calcitonin gene-related peptideCGRP inhibitorchronic migraineClinical trialepisodic migraineeptinezumabhead painHeadacheHeadache journalintravenous eptinezumabLaszlo MechtlerMedical newsmigrainemonoclonal antibodymonthly headache daysmonthly migraine daysPROMISE-1PROMISE-2recent medical news

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok